Plain-English translation of NCT07432958 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Parkinson Disease research guide โPhase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 research study testing a new medication called to see if it can help people with Parkinson's disease who take levodopa but still experience periods when their symptoms suddenly worsen (called "motor fluctuations" or "OFF time"). Researchers want to know if , given in addition to your regular levodopa, can reduce these difficult symptom-free periods. The study compares two different doses of this medication against a placebo (an inactive pill) over about 12 weeks.
Many people with Parkinson's disease who take levodopa experience predictable periods several hours each day when symptoms become much worse, even though they're taking their medication. This treatment gap causes real suffering and limits daily activities. This study is exploring whether the medication can help extend periods of symptom relief and improve quality of life for people dealing with these fluctuations.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will visit the study clinic several times over about 12 weeks. First, there is a screening visit and a 4-week period where your current Parkinson's medications stay the same so doctors can establish a baseline. Then you'll randomly receive either one of two doses of the medication, or a placebo โ neither you nor the study staff will know which one you get. During the 8-week treatment period, you'll take your assigned pill daily along with your regular levodopa, and keep a simple diary at home tracking when your symptoms improve or worsen. The study team may make small adjustments to your levodopa dose if needed during treatment.
AI-generated summary from trial data ยท Aug 23, 2026 ยท Not medical advice
United States